Regeneron COVID-19 Antibody Therapy Approved for Injection
In a move to combat treatment delay, as well as to meet the demand for antibody drugs, the U.S has approved Regeneron Pharmaceutical’s lower dose COVID-19 antibody cocktail that can be administered through injection. The therapy, REGEN-COV, is now permitted to...
FDA Authorizes Cognoa Pediatric Autism (ASD) Diagnosis Device
The U.S Food and Drug Administration (FDA) authorized the marketing of unique autism diagnostic device developed by Cognoa to help diagnose autism spectrum disorder (ASD) in young children between 18 months and 5 years of age. Using a machine learning- based software...
Possible Link Between Myocarditis in Young Males and Pfizer Vaccine
Israel’s Ministry of Health has found a possible link between myocarditis (heart inflammation) in males aged 16-30 and the second Pfizer vaccine. In examining the matter, the Ministry has disclosed the findings of its commissioned study stating that among the total 5...
FDA Approves Amgen’s Lumakras for Lung Cancer Mutation
The U.S. Food and Drug Administration (FDA) has given Amgen’s Lumakras (sotorasib) accelerated approval as a treatment for patients diagnosed with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) - the first FDA approved treatment...
Fennec Pharmaceuticals Resubmits NDA for PEDMARK™
Fennec Pharmaceuticals has resubmitted their New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARK™, a unique sodium thiosulfate formulation. PEDMARK is designed to prevent ototoxicity caused by cisplatin chemotherapy in patients under...
FDA Places Restrictions for Obeticholic Acid (Ocaliva)
The U.S. Food and Drug Administration (FDA) has placed restrictions on the use of obeticholic acid (Ocaliva of Intercept Pharmaceuticals) in patients with primary biliary cholangitis (PBC) and advanced cirrhosis due to risk for serious liver injury. The restriction...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com